“Today’s approval offers the medical community an important tool for managing patients taking Dabigatran (Pradaxa) in emergency or life-threatening situations when bleeding can’t be controlled.” Products in the FDA’s Center for Drug Evaluation and Research. “The anticoagulant effects of Dabigatran (Pradaxa) are important and life-saving for some patients, but there are situations where reversal of the drug’s effects is medically necessary,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Praxbind to the rescue. Onasemnogene abeparvovec-xioi (Zolgensma).IDICAP: An Integrated Drug Intervention for Cancer Panel.Partners Health Care / Personalized Medicine.digital therapeutics in theragenomic medicine.The Human Heredity and Health in Africa (H3Africa).Open Source Pharma (OSP, Medicine for All).EUPATI The European Patients’ Academy on Therapeutic Innovation.Alliance for Cancer Gene Therapy (ACGT).

Clinical Pharmacogenetics Implementation Consortium.China Food & Drug Administration (CFDA).The Medicines Control Council (MCC), South Africa.American Food & Drug Administration (FDA).drugs: risk evaluation and mitigation strategies (REMS).theragenomics: allele-related guideline information.theragenomics: drug labels with annotated information.

Idarucizumab fda approval